Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.”In the company’s words, NCT01244659 on ClinicalTrials.gov
- Tested for
- Renal Transplant
- Main trialPhase 3
- “Comparison of safety and efficacy of immunosuppressive regiments using tacrolimus from EMS and Prograf® in post renal transplanted patients.”In the company’s words, NCT01244659 on ClinicalTrials.gov
- Copy of
- Prograf (Astellas)Tested side by side with the original in NCT01244659
Other drugs for Renal Transplant
- PegcetacoplanApellis Pharmaceuticals, Inc. · Phase 3
- IptacopanNovartis · Phase 3
- ADX-038ADARx Pharmaceuticals, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Withdrawn | Aug 2014 | A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026